confirmed GMFb:actin complexes. Subcellular localization of GMFb only changed with cytochalasin D. In primary embryonic forebrain cultures and RA treated cells, GMFb localized to axons and growth cones. Transfection of wild-type GMFb but not a Cterminal deletion mutant promoted process outgrowth. Phosphorylated GMFb (pGMFb) expression was found in adult brain and low grade gliomas, but not in embryonic brain or glioblastoma. Conclusions: GMFb binds directly to the actin cytoskeleton and is an ADF. GMFb''s phosphorylated form is highly expressed in the differentiated nervous system and low grade gliomas. Future studies will determine whether GMFb or pGMFb expression correlates with patient survival. Using the GMFb knockout mouse, the role of GMFb in glioma tumor invasion and signaling will be addressed in vivo. From the time of diagnosis of a primary malignant brain tumor (PMBT) and throughout the illness trajectory, the patient and intimate partner face many psychosocial challenges ranging from fear and uncertainty to hope and loss. While many patients diagnosed with cancer may go on to live with cancer as a chronic illness, this may not be said of individuals diagnosed with a PMBT, in particular those diagnosed with a glioma, the most common form of brain tumor. Gliomas are associated with a short disease trajectory and multiple deficits (functional, cognitive and psychiatric). What makes the PMBT experience unique from other cancers is that the intimate partner must not only deal with the diagnosis of cancer in their spouse but the accompanying personality, functional and behavioral changes wrought by the disease. It is also not uncommon for the spouse to grieve the loss of the person they once knew often before physical death occurs. This presentation will provide an overview of: 1) key stressors faced by patients and families; 2) and, strategies to more effectively support psychosocial health and wellbeing for patients and families living with and affected by PMBTs. Highlights will be drawn from an ongoing couples study exploring quality of life within the context of PBMT as well as the authors psychotherapy practice. Background: T-cell PCNSLs comprise less than 4% of all primary central nervous system lymphomas (PCNSLs) and appear to have a worse prognosis than B cell PCNSLs. Objective of this study was to gain a more in depth un1derstanding of clinical presentation of the disease and treatment outcomes that may affect patient survival. Methods: Systematic review of the literature was performed using PubMed database from 1983 to 2013. Inclusion criteria consisted of articles having detailed
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